Trevanic

Trevanic is a preclinical-stage biotechnology company focused on the development of theta-defensins, a unique class of macrocyclic peptides with potent immunomodulatory and antimicrobial properties. The company's lead candidate, RTD-1 (Rhesus theta-defensin 1), is being developed to treat life-threatening inflammatory conditions such as sepsis and chronic autoimmune diseases like rheumatoid arthritis. Trevanic's technology platform leverages the exceptional stability and multi-target mechanism of these cyclic peptides to neutralize pro-inflammatory cytokines and modulate the innate immune response. Founded on research from the University of California, Irvine and the University of Southern California, the company aims to address significant unmet needs in infectious and inflammatory medicine.